Skip to main content
Erschienen in: Pediatric Nephrology 11/2012

01.11.2012 | Review

Cystinuria: mechanisms and management

verfasst von: Donna J. Claes, Elizabeth Jackson

Erschienen in: Pediatric Nephrology | Ausgabe 11/2012

Einloggen, um Zugang zu erhalten

Abstract

Cystinuria is a relatively uncommon cause of pediatric stone disease, but has significant morbidity if not properly controlled because of its significant stone recurrence rate. Cystinuria is caused by the inability of the renal tubules to reabsorb filtered cystine, which is poorly soluble at a typical urine pH <7. Although many advances have been made in the understanding of the genetic and physiological basis of cystinuria, the cornerstones of treatment still involve stone prevention with dietary measures and pharmacological therapy, coupled with surgical interventions for stone removal. Pharmacological treatments can carry significant side effects that must be monitored and can limit therapy as well as impede compliance. Most patients will require surgical intervention for stone removal, although compliance with prevention strategies reduces the need for intervention.
Literatur
1.
Zurück zum Zitat Knoll T, Zollner A, Wendt-Nordahl G, Michel MS, Alken P (2005) Cystinuria in childhood and adolescence: recommendations for diagnosis, treatment, and follow-up. Pediatr Nephrol 20:19–24PubMedCrossRef Knoll T, Zollner A, Wendt-Nordahl G, Michel MS, Alken P (2005) Cystinuria in childhood and adolescence: recommendations for diagnosis, treatment, and follow-up. Pediatr Nephrol 20:19–24PubMedCrossRef
3.
Zurück zum Zitat Rogers A, Kalakish S, Desai RA, Assimos DG (2007) Management of cystinuria. Urol Clin North Am 34:347–362PubMedCrossRef Rogers A, Kalakish S, Desai RA, Assimos DG (2007) Management of cystinuria. Urol Clin North Am 34:347–362PubMedCrossRef
4.
5.
Zurück zum Zitat Dello Strologo L, Pras E, Pontesilli C, Beccia E, Ricci-Barbini V, de Sanctis L, Ponzone A, Gallucci M, Bisceglia L, Zelante L, Jimenez-Vidal M, Font M, Zorzano A, Rousaud F, Nunes V, Gasparini P, Palacin M, Rizzoni G (2002) Comparison between SLC3A1 and SLC7A9 cystinuria patients and carriers: a need for a new classification. J Am Soc Nephrol 13:2547–2553PubMedCrossRef Dello Strologo L, Pras E, Pontesilli C, Beccia E, Ricci-Barbini V, de Sanctis L, Ponzone A, Gallucci M, Bisceglia L, Zelante L, Jimenez-Vidal M, Font M, Zorzano A, Rousaud F, Nunes V, Gasparini P, Palacin M, Rizzoni G (2002) Comparison between SLC3A1 and SLC7A9 cystinuria patients and carriers: a need for a new classification. J Am Soc Nephrol 13:2547–2553PubMedCrossRef
6.
Zurück zum Zitat Worcester EM, Coe FL, Evan AP, Parks JH (2006) Reduced renal function and benefits of treatment in cystinuria vs other forms of nephrolithiasis. BJU Int 97:1285–1290PubMedCrossRef Worcester EM, Coe FL, Evan AP, Parks JH (2006) Reduced renal function and benefits of treatment in cystinuria vs other forms of nephrolithiasis. BJU Int 97:1285–1290PubMedCrossRef
7.
Zurück zum Zitat Coe FL, Evan AP, Worcester EM, Lingeman JE (2010) Three pathways for human kidney stone formation. Urol Res 38:147–160PubMedCrossRef Coe FL, Evan AP, Worcester EM, Lingeman JE (2010) Three pathways for human kidney stone formation. Urol Res 38:147–160PubMedCrossRef
8.
Zurück zum Zitat Evan AP, Coe FL, Lingeman JE, Shao Y, Matlaga BR, Kim SC, Bledsoe SB, Sommer AJ, Grynpas M, Phillips CL, Worcester EM (2006) Renal crystal deposits and histopathology in patients with cystine stones. Kidney Int 69:2227–2235PubMedCrossRef Evan AP, Coe FL, Lingeman JE, Shao Y, Matlaga BR, Kim SC, Bledsoe SB, Sommer AJ, Grynpas M, Phillips CL, Worcester EM (2006) Renal crystal deposits and histopathology in patients with cystine stones. Kidney Int 69:2227–2235PubMedCrossRef
9.
Zurück zum Zitat Palacin M, Fernandez E, Chillaron J, Zorzano A (2001) The amino acid transport system b(o,+) and cystinuria. Mol Membr Biol 18:21–26PubMed Palacin M, Fernandez E, Chillaron J, Zorzano A (2001) The amino acid transport system b(o,+) and cystinuria. Mol Membr Biol 18:21–26PubMed
11.
Zurück zum Zitat Camargo SM, Bockenhauer D, Kleta R (2008) Aminoacidurias: clinical and molecular aspects. Kidney Int 73:918–925PubMedCrossRef Camargo SM, Bockenhauer D, Kleta R (2008) Aminoacidurias: clinical and molecular aspects. Kidney Int 73:918–925PubMedCrossRef
12.
Zurück zum Zitat Font-Llitjos M, Jimenez-Vidal M, Bisceglia L, Di Perna M, de Sanctis L, Rousaud F, Zelante L, Palacin M, Nunes V (2005) New insights into cystinuria: 40 new mutations, genotype-phenotype correlation, and digenic inheritance causing partial phenotype. J Med Genet 42:58–68PubMedCrossRef Font-Llitjos M, Jimenez-Vidal M, Bisceglia L, Di Perna M, de Sanctis L, Rousaud F, Zelante L, Palacin M, Nunes V (2005) New insights into cystinuria: 40 new mutations, genotype-phenotype correlation, and digenic inheritance causing partial phenotype. J Med Genet 42:58–68PubMedCrossRef
13.
Zurück zum Zitat Brauers E, Hozyasz K, Golabek B, Slowik M, Schmidt C, Vester U, Zerres K, Eggermann T (2006) Identification of novel cystinuria mutations in pediatric patients. J Pediatr Urol 2:575–578PubMedCrossRef Brauers E, Hozyasz K, Golabek B, Slowik M, Schmidt C, Vester U, Zerres K, Eggermann T (2006) Identification of novel cystinuria mutations in pediatric patients. J Pediatr Urol 2:575–578PubMedCrossRef
14.
Zurück zum Zitat Botzenhart E, Vester U, Schmidt C, Hesse A, Halber M, Wagner C, Lang F, Hoyer P, Zerres K, Eggermann T (2002) Cystinuria in children: distribution and frequencies of mutations in the SLC3A1 and SLC7A9 genes. Kidney Int 62:1136–1142PubMedCrossRef Botzenhart E, Vester U, Schmidt C, Hesse A, Halber M, Wagner C, Lang F, Hoyer P, Zerres K, Eggermann T (2002) Cystinuria in children: distribution and frequencies of mutations in the SLC3A1 and SLC7A9 genes. Kidney Int 62:1136–1142PubMedCrossRef
15.
Zurück zum Zitat Martens K, Jaeken J, Matthijs G, Creemers JW (2008) Multi-system disorder syndromes associated with cystinuria type I. Curr Mol Med 8:544–550PubMedCrossRef Martens K, Jaeken J, Matthijs G, Creemers JW (2008) Multi-system disorder syndromes associated with cystinuria type I. Curr Mol Med 8:544–550PubMedCrossRef
16.
Zurück zum Zitat Tiselius HG (2010) New horizons in the management of patients with cystinuria. Curr Opin Urol 20:169–173PubMedCrossRef Tiselius HG (2010) New horizons in the management of patients with cystinuria. Curr Opin Urol 20:169–173PubMedCrossRef
17.
Zurück zum Zitat Barbey F, Joly D, Rieu P, Mejean A, Daudon M, Jungers P (2000) Medical treatment of cystinuria: critical reappraisal of long-term results. J Urol 163:1419–1423PubMedCrossRef Barbey F, Joly D, Rieu P, Mejean A, Daudon M, Jungers P (2000) Medical treatment of cystinuria: critical reappraisal of long-term results. J Urol 163:1419–1423PubMedCrossRef
18.
Zurück zum Zitat Geary DF, Schaefer F (2008) Comprehensive pediatric nephrology. Mosby/Elsevier, Philadelphia Geary DF, Schaefer F (2008) Comprehensive pediatric nephrology. Mosby/Elsevier, Philadelphia
19.
Zurück zum Zitat Martins MC, Meyers AA, Whalley NA, Rodgers AL (2002) Cystine: a promoter of the growth and aggregation of calcium oxalate crystals in normal undiluted human urine. J Urol 167:317–321PubMedCrossRef Martins MC, Meyers AA, Whalley NA, Rodgers AL (2002) Cystine: a promoter of the growth and aggregation of calcium oxalate crystals in normal undiluted human urine. J Urol 167:317–321PubMedCrossRef
20.
Zurück zum Zitat Sterrett SP, Penniston KL, Wolf JS Jr, Nakada SY (2008) Acetazolamide is an effective adjunct for urinary alkalization in patients with uric acid and cystine stone formation recalcitrant to potassium citrate. Urology 72:278–281PubMedCrossRef Sterrett SP, Penniston KL, Wolf JS Jr, Nakada SY (2008) Acetazolamide is an effective adjunct for urinary alkalization in patients with uric acid and cystine stone formation recalcitrant to potassium citrate. Urology 72:278–281PubMedCrossRef
21.
Zurück zum Zitat Jaffe IA (1986) Adverse effects profile of sulfhydryl compounds in man. Am J Med 80:471–476PubMedCrossRef Jaffe IA (1986) Adverse effects profile of sulfhydryl compounds in man. Am J Med 80:471–476PubMedCrossRef
22.
Zurück zum Zitat Rumsby PC, Shepherd DM (1981) The effect of penicillamine on vitamin B6 function in man. Biochem Pharmacol 30:3051–3053PubMedCrossRef Rumsby PC, Shepherd DM (1981) The effect of penicillamine on vitamin B6 function in man. Biochem Pharmacol 30:3051–3053PubMedCrossRef
23.
Zurück zum Zitat Tomono I, Abe M, Matsuda M (1973) Effect of penicillamine (a vitamin B6 antagonist) on pyridoxal enzymes. J Biochem 74:587–592PubMed Tomono I, Abe M, Matsuda M (1973) Effect of penicillamine (a vitamin B6 antagonist) on pyridoxal enzymes. J Biochem 74:587–592PubMed
24.
Zurück zum Zitat Dello Strologo L, Laurenzi C, Legato A, Pastore A (2007) Cystinuria in children and young adults: success of monitoring free-cystine urine levels. Pediatr Nephrol 22:1869–1873PubMedCrossRef Dello Strologo L, Laurenzi C, Legato A, Pastore A (2007) Cystinuria in children and young adults: success of monitoring free-cystine urine levels. Pediatr Nephrol 22:1869–1873PubMedCrossRef
25.
Zurück zum Zitat DeBerardinis RJ, Coughlin CR II, Kaplan P (2008) Penicillamine therapy for pediatric cystinuria: experience from a cohort of American children. J Urol 180:2620–2623PubMedCrossRef DeBerardinis RJ, Coughlin CR II, Kaplan P (2008) Penicillamine therapy for pediatric cystinuria: experience from a cohort of American children. J Urol 180:2620–2623PubMedCrossRef
26.
Zurück zum Zitat Sloand JA, Izzo JL Jr (1987) Captopril reduces urinary cystine excretion in cystinuria. Arch Intern Med 147:1409–1412PubMedCrossRef Sloand JA, Izzo JL Jr (1987) Captopril reduces urinary cystine excretion in cystinuria. Arch Intern Med 147:1409–1412PubMedCrossRef
27.
Zurück zum Zitat Coe FL, Clark C, Parks JH, Asplin JR (2001) Solid phase assay of urine cystine supersaturation in the presence of cystine binding drugs. J Urol 166:688–693PubMedCrossRef Coe FL, Clark C, Parks JH, Asplin JR (2001) Solid phase assay of urine cystine supersaturation in the presence of cystine binding drugs. J Urol 166:688–693PubMedCrossRef
28.
Zurück zum Zitat Nakagawa Y, Asplin JR, Goldfarb DS, Parks JH, Coe FL (2000) Clinical use of cystine supersaturation measurements. J Urol 164:1481–1485PubMedCrossRef Nakagawa Y, Asplin JR, Goldfarb DS, Parks JH, Coe FL (2000) Clinical use of cystine supersaturation measurements. J Urol 164:1481–1485PubMedCrossRef
29.
Zurück zum Zitat Pietrow PK, Auge BK, Weizer AZ, Delvecchio FC, Silverstein AD, Mathias B, Albala DM, Preminger GM (2003) Durability of the medical management of cystinuria. J Urol 169:68–70PubMedCrossRef Pietrow PK, Auge BK, Weizer AZ, Delvecchio FC, Silverstein AD, Mathias B, Albala DM, Preminger GM (2003) Durability of the medical management of cystinuria. J Urol 169:68–70PubMedCrossRef
30.
Zurück zum Zitat Assimos DG, Leslie SW, Ng C, Streem SB, Hart LJ (2002) The impact of cystinuria on renal function. J Urol 168:27–30PubMedCrossRef Assimos DG, Leslie SW, Ng C, Streem SB, Hart LJ (2002) The impact of cystinuria on renal function. J Urol 168:27–30PubMedCrossRef
31.
Zurück zum Zitat Landau EH, Shenfeld OZ, Pode D, Shapiro A, Meretyk S, Katz G, Katz R, Duvdevani M, Hardak B, Cipele H, Hidas G, Yutkin V, Gofrit ON (2009) Extracorporeal shock wave lithotripsy in prepubertal children: 22-year experience at a single institution with a single lithotriptor. J Urol 182:1835–1839PubMedCrossRef Landau EH, Shenfeld OZ, Pode D, Shapiro A, Meretyk S, Katz G, Katz R, Duvdevani M, Hardak B, Cipele H, Hidas G, Yutkin V, Gofrit ON (2009) Extracorporeal shock wave lithotripsy in prepubertal children: 22-year experience at a single institution with a single lithotriptor. J Urol 182:1835–1839PubMedCrossRef
32.
Zurück zum Zitat Ahmed K, Khan MS, Thomas K, Challacombe B, Bultitude M, Glass J, Tiptaft R, Dasgupta P (2008) Management of cystinuric patients: an observational, retrospective, single-centre analysis. Urol Int 80:141–144PubMedCrossRef Ahmed K, Khan MS, Thomas K, Challacombe B, Bultitude M, Glass J, Tiptaft R, Dasgupta P (2008) Management of cystinuric patients: an observational, retrospective, single-centre analysis. Urol Int 80:141–144PubMedCrossRef
33.
Zurück zum Zitat Kim SC, Burns EK, Lingeman JE, Paterson RF, McAteer JA, Williams JC Jr (2007) Cystine calculi: correlation of CT-visible structure, CT number, and stone morphology with fragmentation by shock wave lithotripsy. Urol Res 35:319–324PubMedCrossRef Kim SC, Burns EK, Lingeman JE, Paterson RF, McAteer JA, Williams JC Jr (2007) Cystine calculi: correlation of CT-visible structure, CT number, and stone morphology with fragmentation by shock wave lithotripsy. Urol Res 35:319–324PubMedCrossRef
34.
Zurück zum Zitat Rule AD, Bergstralh EJ, Melton LJ III, Li X, Weaver AL, Lieske JC (2009) Kidney stones and the risk for chronic kidney disease. Clin J Am Soc Nephrol 4:804–811PubMedCrossRef Rule AD, Bergstralh EJ, Melton LJ III, Li X, Weaver AL, Lieske JC (2009) Kidney stones and the risk for chronic kidney disease. Clin J Am Soc Nephrol 4:804–811PubMedCrossRef
35.
Zurück zum Zitat Rule AD, Krambeck AE, Lieske JC (2011) Chronic kidney disease in kidney stone formers. Clin J Am Soc Nephrol 6:2069–2075PubMedCrossRef Rule AD, Krambeck AE, Lieske JC (2011) Chronic kidney disease in kidney stone formers. Clin J Am Soc Nephrol 6:2069–2075PubMedCrossRef
36.
Zurück zum Zitat Wendt-Nordahl G, Sagi S, Bolenz C, Alken P, Michel MS, Knoll T (2008) Evaluation of cystine transport in cultured human kidney cells and establishment of cystinuria type I phenotype by antisense technology. Urol Res 36:25–29PubMedCrossRef Wendt-Nordahl G, Sagi S, Bolenz C, Alken P, Michel MS, Knoll T (2008) Evaluation of cystine transport in cultured human kidney cells and establishment of cystinuria type I phenotype by antisense technology. Urol Res 36:25–29PubMedCrossRef
37.
Zurück zum Zitat Rimer JD, An Z, Zhu Z, Lee MH, Goldfarb DS, Wesson JA, Ward MD (2010) Crystal growth inhibitors for the prevention of L-cystine kidney stones through molecular design. Science 330:337–341PubMedCrossRef Rimer JD, An Z, Zhu Z, Lee MH, Goldfarb DS, Wesson JA, Ward MD (2010) Crystal growth inhibitors for the prevention of L-cystine kidney stones through molecular design. Science 330:337–341PubMedCrossRef
Metadaten
Titel
Cystinuria: mechanisms and management
verfasst von
Donna J. Claes
Elizabeth Jackson
Publikationsdatum
01.11.2012
Verlag
Springer-Verlag
Erschienen in
Pediatric Nephrology / Ausgabe 11/2012
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-011-2092-6

Weitere Artikel der Ausgabe 11/2012

Pediatric Nephrology 11/2012 Zur Ausgabe

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Häufigste Gründe für Brustschmerzen bei Kindern

06.05.2024 Pädiatrische Diagnostik Nachrichten

Akute Brustschmerzen sind ein Alarmsymptom par exellence, schließlich sind manche Auslöser lebensbedrohlich. Auch Kinder klagen oft über Schmerzen in der Brust. Ein Studienteam ist den Ursachen nachgegangen.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärztinnen und Psychotherapeuten.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.